DALIVIT Price

Overview

Welcome to Dwaey, specifically on DALIVIT page.
This medicine contains an important and useful components, as it consists of
Vitamin - A / B1 / B2 / B6 / Nicotinamide / C / Dis available in the market in concentration

Name

Almotriptan

Precaution

Hypersensitivity to sulfonamides. Hepatic or moderate-severe renal impairment. Caution when used in patients with a history of seizures. May significantly increase BP. May cause drowsiness. Children <18 yr. Pregnancy, lactation. Lactation: excretion in milk unknown; use with caution

Indication

Migraine headache, Acute migraine attacks

Contra indication

Underlying CV disease e.g. ischaemic heart disease or coronary artery vasospasm. Uncontrolled hypertension. Severe hepatic or renal impairment. Prophylaxis of migraine, hemiplegic or basilar migraine; cluster headache. Use within 24 hr of another 5-HT1 agonist; use within 24 hr of ergotamine derivative; concurrent use or within 2 wk of discontinuing an MAOI.

Side Effect

1-10% Somnolence (1-5%),Dizziness (3-4%),Nausea (1-3%),Vomiting (2%),Dry mouth (1-2%),Headache (1-2%),Nausea (1-2%),Paresthesia (1-2%),Paresthesia (1%),Somnolence (>1%) <1% Infrequent (0.01-0.001%) Anxiety, asthenia, chills, CNS stimulation, fatigue, hypesthesia, tremor, Pruitus, rash, Diaphoresis, dysmenorrhea, hyperglycemia, increased thirst, Abdominal cramp, gastroenteritis Back pain, myalgia, neck pain, rigid neck, Increased CPK, Bronchitis, chest pain, dyspnea, pharyngitis, rhinitis, sinusitis, Conjunctivitis, tinnitis, vertigo Potentially Fatal: Serious cardiac events.

Pregnancy Category ID

3

Mode of Action

Almotriptan is a selective serotonin agonist which acts mainly on the 5-HT1 receptors and produces cranial vasodilation. It is used for the acute treatment of migraine.

Interaction

Increased risk of serotonin syndrome when used with SSRIs or serotonin norepinephrine reuptake inhibitors. Increased plasma concentrations when used with verapamil, ketoconazole or other potent CYP450 inhibitors. Potentially Fatal: Severe vasospastic reactions may occur when given within 24 hr of treatment with another 5-HT1 agonist, or an ergotamine-containing or ergot-like medication. Avoid usage with or within 2 wk of stopping treatment with a MAOI.

Pregnancy Category Note

Information not available

Adult Dose

Child Dose

Renal Dose

Administration